Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIV-uninfected patients.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 19814621.
- Also identified by DOI 10.1086/630205.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Information on the rate and timing of hepatitis C virus (HCV) relapse after treatment with pegylated interferon plus ribavirin is scarce. Among 604 patients treated for chronic hepatitis C, the 386 who were human immunodeficiency virus (HIV) positive attained an end-of-treatment response less frequently and experienced relapse more often than did the 218 who were HIV negative. However, episodes of HCV relapse occurred before week 12 in most cases, regardless of HIV status.
Medical subject headings
- Antiviral Agents
- HIV Infections
- Hepacivirus
- Hepatitis C
- Interferon-alpha
- Polyethylene Glycols
- Ribavirin